Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NanoString gene expression data of OCI-C5x and OCI-P5x

ABSTRACT: Gene expression data of two ovarian carcinoma patient-derived cells was analyzed with respect to high-throughput functional siRNA screens and small-molecule screens.

ORGANISM(S): Homo sapiens

PROVIDER: GSE153440 | GEO | 2020/06/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression Data from Leukemia Patients Supporting Personalized Functional Cancer Genomics Analyses

Project description:A set of expression samples used to support a personalized genomics analysis with regards to functional assays (e.g. siRNA or small molecule screens) 50 patient samples from a variety of disease types and several tissues

2013-10-04 | E-GEOD-42731 | biostudies-arrayexpress

RNA-Seq expression profiling of clonal populations from the OCI-C5x patient-derived ovarian clear cell carcinoma cell line

Project description:Intratumoral heterogeneity is well-recognized but its impact on tumor progression is unclear. Here, we derived unbiased clonal populations from OCI-C5x, a patient-derived ovarian clear cell carcinoma cell line, and assessed their tumorigenicity and tracked their fate during tumor progression. Results provide insight into intratumoral heterogeneity of clear cell carcinoma transcriptomes.

2020-09-11 | GSE123426 | GEO

BRD4 represses CBX5

Project description:BRD4 is amplified and/or up-regiulated in a subset of ovarian cancer which correlates with a poor survival siRNA sensitization screens in the presence of CHK1 inhibitor, LY2606368, identify BRD4 as a therapeutic target in ovarian cancer. BRD4 suppression by either siRNA or using JQ1 increases CBX5 expression

2016-05-01 | GSE78704 | GEO

RNA profiling from ovarian FFPE specimens (Nanostring)

Project description:To study feasibility of gene expression profiling from FFPE tissues using NanoString nCounter platform, we designed a pilot study utilizing samples from ovarian cancer cohort. We selected samples from large-scale epidemiologic studies and clinical trials representative of a wide variety of fixation times, block ages and block storage conditions. five serous carcinoma and six clear cell carcinoma samples with technical replicates

2014-07-01 | E-GEOD-55056 | biostudies-arrayexpress

Expression Data from Leukemia Patients Supporting Personalized Functional Cancer Genomics Analyses

Project description:A set of expression samples used to support a personalized genomics analysis with regards to functional assays (e.g. siRNA or small molecule screens)

2013-10-04 | GSE42731 | GEO

NanoString nCounter Cancer CN panel assay CNV detection of high-grade serous carcinoma samples

Project description:CNVs detection using 13 samples’ pairs of (12 samples’ pairs of histologically confirmed diagnosis of high-grade serous carcinoma and one patient with endometrioid carcinoma and matching normal tissues. Samples have IHC status for p53, WT1, Ki-67, PAX-8, and TNM classification according to WHO Classification of Tumors. Please cite the original atricle: Grebnev, P.A.; Meshkov, I.O.; Ershov, P.V.; Makhotenko, A.V.; Azarian, V.B.; Erokhina, M.V.; Galeta, A.A.; Zakubanskiy, A.V.; Shingalieva, O.S.; Tregubova, A.V.; et al. Benchmarking of Approaches for Gene Copy-Number Variation Analysis and Its Utility for Genetic Aberration Detection in High-Grade Serous Ovarian Carcinomas. Cancers 2024, 16, 3252. https://doi.org/10.3390/cancers16193252

2024-09-24 | GSE244329 | GEO

A genome-wide CRISPR/Cas9 screen identifies therapeutic targets required for the tumorigenesis of ovarian clear cell carcinoma (OCCC).

Project description:To identify genes critical for the proliferation of ovarian clear cell carcinoma (OCCC), we performed CRISPR/CAS9 screens against the OCCC cell lines OVICE, ES2, TOV21G and JHOC5 using the TKOv3 sgRNA library.

2022-06-08 | GSE189405 | GEO

Integrated Genetic and Pharmacologic Interrogation of Rare Cancers

Project description:<p>Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen. Integration of these data identified CDK4 and XPO1 as potential therapeutic targets.</p>

| phs001121 | dbGaP

Liver lineage confers sensitivity of cancer cells to sulfonation-dependent alkylators

Project description:Adult liver malignancies, including intrahepatic cholangiocarcinoma and hepatocellular carcinoma, are the 2nd leading cause of cancer related death worldwide. The majority of patients are currently treated with either combination chemotherapy or immunotherapy, respectively, without specific biomarkers for patient selection. Here, using high-throughput screens, proteomics, and in vitro resistance models, we identify the small molecule, YC-1, as selectively active against a defined subset of cell lines derived from both major liver cancer types. We demonstrate that selectivity in vitro and in vivo is determined by expression of a human cytosolic sulfotransferase – the liver resident enzyme SULT1A1, which sulfonates YC-1. Sulfonation stimulates covalent binding of YC-1 to lysine residues in protein targets, enriching for RNA binding factors. Using computational analysis as well as structural modeling, we also define a wider group of structurally related SULT1A1-activated small molecules with distinct target profiles, which together constitute an untapped small molecule class. These studies provide a foundation for pre-clinical development of these agents and point to the broader potential of exploiting the liver lineage enzyme SULT1A1 for selective targeting strategies.

2023-01-24 | GSE168791 | GEO

USP19 and RPL23 as candidate prognostic markers in advanced-stage high-grade serous ovarian carcinoma

Project description:Ovarian cancer is one of the leading causes of death among patients with gynecological malignancies worldwide. To identify prognostic markers for ovarian cancer, we performed RNA-sequencing and analyzed the transcriptome data from 51 patients who received conventional therapies for high-grade serous ovarian carcinoma (HGSC). Patients with early-stage (I or II) HGSC exhibited higher immune gene expression than patients with advanced stage (III or IV) HGSC. To predict the prognosis of HGSC patients, we created machine learning-based models and identified RPL23 and USP19 as candidate prognostic markers. Specifically, patients with higher RPL23 mRNA levels had a worse prognosis and patients with higher USP19 mRNA levels had a better prognosis. This model was then used to analyze HGSC patient data hosted on The Cancer Genome Atlas; this exercise validated the prognostic abilities of these two genes with respect to patient survival. Taken together, the transcriptome profiles of RPL23 and USP19 determined using a machine-learning model could serve as prognostic markers in HGSC patients receiving conventional therapy.

2021-08-09 | GSE165808 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data